<code id='184922D9D4'></code><style id='184922D9D4'></style>
    • <acronym id='184922D9D4'></acronym>
      <center id='184922D9D4'><center id='184922D9D4'><tfoot id='184922D9D4'></tfoot></center><abbr id='184922D9D4'><dir id='184922D9D4'><tfoot id='184922D9D4'></tfoot><noframes id='184922D9D4'>

    • <optgroup id='184922D9D4'><strike id='184922D9D4'><sup id='184922D9D4'></sup></strike><code id='184922D9D4'></code></optgroup>
        1. <b id='184922D9D4'><label id='184922D9D4'><select id='184922D9D4'><dt id='184922D9D4'><span id='184922D9D4'></span></dt></select></label></b><u id='184922D9D4'></u>
          <i id='184922D9D4'><strike id='184922D9D4'><tt id='184922D9D4'><pre id='184922D9D4'></pre></tt></strike></i>

          
          WSS
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment